Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Azitra, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
Fr | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
Mi | Azitra stock soars after first patient dosed in Phase 1/2 trial | 3 | Investing.com | ||
AZITRA Aktie jetzt für 0€ handeln | |||||
Mi | Azitra doses first patient in phase 1/2 trial for cancer therapy rash | 2 | Investing.com | ||
Mi | Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash | 157 | PR Newswire | BRANFORD, Conn., Aug. 27, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing... ► Artikel lesen | |
22.08. | Stock Market Today: Nasdaq, Dow, S&P 500 Futures Rise Ahead Of Powell's Speech At Jackson Hole-EpicQuest, Zoom, Azitra Stocks In Focus | 4 | Benzinga.com | ||
20.08. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.08. | Azitra reports Q2 results | 1 | Seeking Alpha | ||
11.08. | Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates | 267 | PR Newswire | BRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing... ► Artikel lesen | |
11.08. | Azitra to implement 1-for-6.66 reverse stock split | 1 | Seeking Alpha | ||
11.08. | Azitra, Inc. Announces Reverse Stock Split | 156 | PR Newswire | Common Stock Will Begin Trading on a Split-Adjusted Basis on August 21, 2025
BRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR)... ► Artikel lesen | |
11.08. | Azitra, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
11.08. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
18.07. | Azitra, Inc. - S-1, General form for registration of securities | 3 | SEC Filings | ||
03.07. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
17.06. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
17.06. | Azitra, Inc.: Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome | 165 | PR Newswire | Drug candidate ATR12-351 has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application site
Trial is 50% enrolled... ► Artikel lesen | |
14.05. | Azitra GAAP EPS of -$0.23 | 1 | Seeking Alpha | ||
13.05. | Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates | 156 | PR Newswire | BRANFORD, Conn., May 13, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
13.05. | Azitra, Inc. - 8-K, Current Report | 11 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
INOVIO PHARMACEUTICALS | 1,980 | -1,98 % | INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug | ||
ADAPTIMMUNE THERAPEUTICS | 0,050 | -1,98 % | Adaptimmune Therapeutics PLC - 8-K, Current Report | ||
QIAGEN | 39,710 | +0,16 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 58,58 | +0,72 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
BIONTECH | 85,65 | +0,06 % | Paukenschlag beim Übernahmekandidaten! 100 %-Aktie BioNxt Solutions lässt BioNTech und Co. hinter sich! | Die Aktie von BioNxt ist endlich angesprungen. Anfang Juli hatten wir zuletzt auf die Chancen des kanadisch-deutschen Biowissenschaftsunternehmens hingewiesen. Seitdem ist die Aktie um fast 100 % gestiegen... ► Artikel lesen | |
IMMUNOVANT | 14,690 | -0,88 % | Immunovant, Inc. - 8-K, Current Report | ||
ARS PHARMACEUTICALS | 11,610 | -9,72 % | ARS Pharma drops 9% as Lupin files application for generic neffy | ||
EVOTEC | 6,000 | +0,03 % | Aktien KW 34 Nix passiert? Montag Powell Schub? Aber: Woher die guten Nachrichten? Nvdia am Mittwoch als Lackmustest? Märkte heissgelaufen? News. Rheinmetall. Evotec. Stratec. YOC. Doc Morris. SFC Energy. Multitude. Circus. Delignit. Lang und Schwarz. Kap | Aktien: Diese Woche hnadelte der Markt in einer engen Range von unter 300 Punkten. Schien alles auf Powell's Rede zu warten. Und für die Bullen scheint es sich gelohnt zu haben, die Auguren deuteten... ► Artikel lesen | |
LENZ THERAPEUTICS | 38,630 | +1,13 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 23,710 | -2,91 % | H.C. Wainwright hebt Kursziel für Summit Therapeutics auf 50 US-Dollar an | ||
AVIDITY BIOSCIENCES | 46,540 | -4,20 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
ARRIVENT BIOPHARMA | 19,120 | -0,52 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2025 Financial Results | Positive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient... ► Artikel lesen | |
RAPPORT THERAPEUTICS | 17,630 | +4,94 % | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS)... ► Artikel lesen | |
CRISPR THERAPEUTICS | 44,200 | -0,45 % | 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) | ||
RECURSION PHARMACEUTICALS | 4,690 | -3,60 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today |